Background: Oxidative balance score (OBS) is a composite measure of oxidative stress-related exposures. The aim of this study was to investigate the association between OBS, end-stage renal disease (ESRD), and cardiovascular disease (CVD). Methods: Using data from the Chronic Renal Insufficiency Cohort, we calculated the main exposure OBS by summing up 12 apriori-defined pro- and antioxidant factors obtained from the diet history questionnaire and lifestyle assessment. We divided OBS into quartiles (Q1-Q4), with Q1 (predominance of pro-oxidants) as the reference. We analyzed OBS quartiles as an ordinal variable. Crude and adjusted hazards ratios (HRs) and 95% CIs were estimated using Cox proportional hazards models for time to ESRD and CVD. Results: Compared to Q1, Q4 (high antioxidant) was associated with ESRD in the crude model (HR 1.35, 95% CI 1.08-1.69) and adjusting for age, sex, and race (HR 1.36, 95% CI 1.09-1.71) but not in the fully adjusted model (HR 1.12, 95% CI 0.84-1.51). HR of ESRD increased as the OBS quartiles increased in the crude model (ptrend < 0.05) but not in the fully adjusted model (ptrend = 0.30). Compared to Q1, Q4 was associated with CVD in the crude (HR 1.33, 95% CI 1.06-1.68) but not adjusted models. The HR of CVD increased with an increase in OBS quartiles in the crude model (ptrend < 0.05). Conclusion: The reverse association between OBS and progression to ESRD suggests that perhaps the effect of oxidative balance-related exposure is different in the setting of established chronic kidney disease.

Keywords:
Pro-oxidant, Antioxidant, Chronic kidney disease, End-stage renal disease, Cardiovascular disease, Oxidative balance
1.
Sies H: Oxidative stress: oxidants and antioxidants. Exp Physiol 1997;82:291-295.
2.
Himmelfarb J: Uremic toxicity, oxidative stress, and hemodialysis as renal replacement therapy. Semin Dial 2009;22:636-643.
3.
Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, et al: Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004;65:1009-1016.
4.
Landray MJ, Wheeler DC, Lip GY, Newman DJ, Blann AD, McGlynn FJ, et al: Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis 2004;43:244-253.
5.
Okamura DM, Lopez-Guisa JM, Koelsch K, Collins S, Eddy AA: Atherogenic scavenger receptor modulation in the tubulointerstitium in response to chronic renal injury. Am J Physiol Renal Physiol 2007;293:F575-F585.
6.
Simmons EM, Langone A, Sezer MT, Vella JP, Recupero P, Morrow JD, et al: Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patients. Transplantation 2005;79:914-919.
7.
Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32(5 suppl 3):S112-S119.
8.
Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH: Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004;164:659-663.
9.
Becker BN, Himmelfarb J, Henrich WL, Hakim RM: Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol 1997;8:475-486.
10.
Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, et al: Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000;58:353-362.
11.
Ziouzenkova O, Asatryan L, Akmal M, Tetta C, Wratten ML, Loseto-Wich G, et al: Oxidative cross-linking of ApoB100 and hemoglobin results in low density lipoprotein modification in blood. Relevance to atherogenesis caused by hemodialysis. J Biol Chem 1999;274:18916-18924.
12.
Salomon RG, Kaur K, Podrez E, Hoff HF, Krushinsky AV, Sayre LM: HNE-derived 2-pentylpyrroles are generated during oxidation of LDL, are more prevalent in blood plasma from patients with renal disease or atherosclerosis, and are present in atherosclerotic plaques. Chem Res Toxicol 2000;13:557-564.
13.
Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002;62:1524-1538.
14.
Wright ME, Mayne ST, Stolzenberg-Solomon RZ, Li Z, Pietinen P, Taylor PR, et al: Development of a comprehensive dietary antioxidant index and application to lung cancer risk in a cohort of male smokers. Am J Epidemiol 2004;160:68-76.
15.
Van Hoydonck PG, Temme EH, Schouten EG: A dietary oxidative balance score of vitamin C, beta-carotene and iron intakes and mortality risk in male smoking Belgians. J Nutr 2002;132:756-761.
16.
Slattery ML, Lundgreen A, Welbourn B, Wolff RK, Corcoran C: Oxidative balance and colon and rectal cancer: interaction of lifestyle factors and genes. Mutat Res 2012;734:30-40.
17.
Dash C, Goodman M, Flanders WD, Mink PJ, McCullough ML, Bostick RM: Using pathway-specific comprehensive exposure scores in epidemiology: application to oxidative balance in a pooled case-control study of incident, sporadic colorectal adenomas. Am J Epidemiol 2013;178:610-624.
18.
Kong SY, Goodman M, Judd S, Bostick RM, Flanders WD, McClellan W: Oxidative balance score as predictor of all-cause, cancer, and noncancer mortality in a biracial US cohort. Ann Epidemiol 2015;25:256-262.e1.
19.
Dash C, Bostick RM, Goodman M, Flanders WD, Patel R, Shah R, et al: Oxidative balance scores and risk of incident colorectal cancer in a US prospective cohort study. Am J Epidemiol 2015;181:584-594.
20.
Ilori TO, Sun Ro Y, Kong SY, Gutierrez OM, Ojo AO, Judd SE, et al: Oxidative balance score and chronic kidney disease. Am J Nephrol 2015;42:320-327.
21.
Feldman HI, Appel LJ, Chertow GM, Cifelli D, Cizman B, Daugirdas J, et al: The chronic renal insufficiency cohort (CRIC) study: design and methods. J Am Soc Nephrol 2003;14(7 suppl 2):S148-S153.
22.
Lash JP, Go AS, Appel LJ, He J, Ojo A, Rahman M, et al: Chronic renal insufficiency cohort (CRIC) study: baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol 2009;4:1302-1311.
23.
Diet History Questionnaire, Version 1: National Institutes of Health, Applied Research Program, National Cancer Institute. http://riskfactor.cancer.gov/DHQ/.
24.
Subar AF, Thompson FE, Kipnis V, Midthune D, Hurwitz P, McNutt S, et al: Comparative validation of the Block, Willett, and National Cancer Institute food frequency questionnaires: the Eating at America's Table Study. Am J Epidemiol 2001;154:1089-1099.
25.
Goodman M, Bostick RM, Dash C, Flanders WD, Mandel JS: Hypothesis: oxidative stress score as a combined measure of pro-oxidant and antioxidant exposures. Ann Epidemiol 2007;17:394-399.
26.
Gooch K, Culleton BF, Manns BJ, Zhang J, Alfonso H, Tonelli M, et al: NSAID use and progression of chronic kidney disease. Am J Med 2007;120:280.e1-e7.
27.
Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989;321:129-135.
28.
Young FE, Nightingale SL, Temple RA: The preliminary report of the findings of the aspirin component of the ongoing Physicians' Health Study. The FDA perspective on aspirin for the primary prevention of myocardial infarction. JAMA 1988;259:3158-3160.
29.
Hallan SI, Orth SR: Smoking is a risk factor in the progression to kidney failure. Kidney Int 2011;80:516-523.
30.
Orth SR, Hallan SI: Smoking: a risk factor for progression of chronic kidney disease and for cardiovascular morbidity and mortality in renal patients - absence of evidence or evidence of absence? Clin J Am Soc Nephrol 2008;3:226-236.
31.
Smoking: a risk factor for cardiovascular disease. Official satellite to the third European meeting on hypertension. June 19, 1987, Milan, Italy. Proceedings. Am Heart J 1988;115(1 pt 2):239-296.
32.
Mills KT, Chen J, Yang W, Appel LJ, Kusek JW, Alper A, et al: Sodium excretion and the risk of cardiovascular disease in patients with chronic kidney disease. JAMA 2016;315:2200-2210.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.